Osaka Koseinenkin Hospital   Report issue

Academic/Hospital Phase 3
Founded: Fukushima Japan

Organization Overview

First Clinical Trial
2006
NCT01203072
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Osaka Koseinekin Hospital | Osaka Kouseinennkin Hospital

Active Ingredients

Drugs in Phase 3 Trials (3)

edoxaban (savaysa) (6 trials)

enoxaparin (lovenox) (4 trials)

fondaparinux sodium (arixtra) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Embolism (Phase 2)

Embolism and Thrombosis (Phase 2)

Hip Fractures (Phase 3)

Renal Insufficiency (Phase 3)

Thromboembolism (Phase 3)

Thrombosis (Phase 2)

Venous Thromboembolism (Phase 3)

Venous Thrombosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 3